Evidence map›Paper›PMID 42251226›Full record

ReviewJournal of natural medicines2026

The human microbiome as a source of novel bioactive natural products: structures, bioactivities, and biosynthetic insights.

Eun La Kim, Eun Seo Jang, Youngsang Nam, Hyeon-Jeong Hwang, Yeo Jin Lee, Tae Gyun Kim, Chaeyun Hong, Seoung Rak Lee

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eun La Kim *College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Eun Seo Jang *College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Youngsang NamCollege of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Hyeon-Jeong HwangCollege of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Yeo Jin LeeCollege of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Tae Gyun KimCollege of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Chaeyun HongCollege of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea.
Seoung Rak LeeCollege of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, 46241, Republic of Korea. srlee17@pusan.ac.kr.ORCID http://orcid.org/0009-0006-8696-2949

Funding

Korea Basic Science Institute RS-2024-00403999Ministry of Education and Busan Metropolitan City 2025-glocal-02-004-511-002Ministry of Science and ICT, South Korea WISET-2025-392National Research Foundation of Korea RS-2025-23525419
6 · The paper itself

Abstract

The human microbiome, comprising trillions of microorganisms in distinct anatomical locations such as the gut, oral cavity, skin, and vagina, has emerged as a source of bioactive natural products with diverse scaffolds. Through co-evolution with the host, the human microbiome produces small molecules tailored to physicochemical environments that contribute to immune regulation, epithelial barrier maintenance, pathogen defense, and neurochemical signaling. Recent advances in metagenomics, single-cell genomics, synthetic biology, and integrated omics approaches have enabled rapid discovery and structural elucidation of biosynthetic gene clusters (BGCs) and metabolites. Cultivation-driven and genome mining strategies combined with omics analyses have improved the efficiency of discovering microbiome-derived drug leads. These metabolites mediate competitive and cooperative interactions within microbial ecosystems and hold high promise for therapeutic applications such as immunomodulators, anti-infectives, and neuroactive agents. This review outlines the structural features, biosynthetic pathways, and bioactivities of key metabolites across major microbial niches, together with strategies for their discovery, highlighting their potential in advancing drug development and human health.

Indexed as

Biological ProductsMicrobiotaBiosynthetic PathwaysHumansBiological ProductsBiosynthesisChemical structuresHuman microbiomeNatural products

Identifiers

PMID42251226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.